P L Zinzani

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi request reprint Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 9:381-5. 2009
  2. ncbi request reprint Is it really possible to cure hairy cell leukemia patients only with frontline therapy?
    Pier Luigi Zinzani
    Institute of Hematology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy
    Ann Hematol 93:1565-9. 2014
  3. pmc GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers
    Sylvia Hartmann
    Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany
    BMC Cancer 12:586. 2012
  4. pmc Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
    Pier Luigi Zinzani
    1Institute of Hematology L and A Seràgnoli, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 98:1232-6. 2013
  5. doi request reprint The many faces of marginal zone lymphoma
    Pier Luigi Zinzani
    Istituto di Ematologia Seràgnoli Università di Bologna, Bologna, Italy
    Hematology Am Soc Hematol Educ Program 2012:426-32. 2012
  6. ncbi request reprint A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Ann Oncol 23:415-20. 2012
  7. pmc Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L, and A, Seragnoli, University of Bologna, Bologna, Italy
    J Hematol Oncol 5:67. 2012
  8. ncbi request reprint Overview of alemtuzumab therapy for the treatment of T-cell lymphomas
    Pier Luigi Zinzani
    University of Bologna, Bologna, Italy
    Leuk Lymphoma 53:789-95. 2012
  9. doi request reprint Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Curr Oncol Rep 13:407-15. 2011
  10. doi request reprint Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, Bologna, Italy
    Ann Oncol 21:860-3. 2010

Detail Information

Publications113 found, 100 shown here

  1. ncbi request reprint Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 9:381-5. 2009
    ..Recently, the superiority of R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone) over CHOP-like regimens has been demonstrated in elderly and younger patients with low-risk diffuse large B-cell lymphoma...
  2. ncbi request reprint Is it really possible to cure hairy cell leukemia patients only with frontline therapy?
    Pier Luigi Zinzani
    Institute of Hematology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy
    Ann Hematol 93:1565-9. 2014
    ..0 years. There is a need for continuous study in this field to better define the optimal therapeutic regimen and, in particular, the biological issues since at least 20-25 % of HCL patients can be cured with only one treatment. ..
  3. pmc GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers
    Sylvia Hartmann
    Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany
    BMC Cancer 12:586. 2012
    ....
  4. pmc Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
    Pier Luigi Zinzani
    1Institute of Hematology L and A Seràgnoli, S Orsola Malpighi Hospital, Bologna, Italy
    Haematologica 98:1232-6. 2013
    ..Best overall responses were recorded after three or four cycles and showed that brentuximab vedotin provides an effective bridge to further therapeutic interventions. ..
  5. doi request reprint The many faces of marginal zone lymphoma
    Pier Luigi Zinzani
    Istituto di Ematologia Seràgnoli Università di Bologna, Bologna, Italy
    Hematology Am Soc Hematol Educ Program 2012:426-32. 2012
    ..Patients with NMZL, by definition, have lymph node-based disease without involvement of the spleen or extranodal sites. The molecular pathogenesis of NMZL is still unknown...
  6. ncbi request reprint A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Ann Oncol 23:415-20. 2012
    ....
  7. pmc Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L, and A, Seragnoli, University of Bologna, Bologna, Italy
    J Hematol Oncol 5:67. 2012
    ..We report findings in high-risk patients (FL International Prognostic Index [FLIPI] score ≥3, and high tumor burden by modified Groupe d'Etude des Lymphomas Folliculaires [GELF] criteria)...
  8. ncbi request reprint Overview of alemtuzumab therapy for the treatment of T-cell lymphomas
    Pier Luigi Zinzani
    University of Bologna, Bologna, Italy
    Leuk Lymphoma 53:789-95. 2012
    ..Alemtuzumab is an effective alternative option for patients with peripheral T-cell lymphomas and cutaneous T-cell lymphomas. Alemtuzumab may belong to the current standard of care for nodal and cutaneous T-cell lymphomas...
  9. doi request reprint Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Curr Oncol Rep 13:407-15. 2011
    ..The real role of FDG-PET scanning requires prospective studies, and it is hoped that this may allow the de-escalation of radiation therapy accordingly to yield reliable prognostic information...
  10. doi request reprint Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, Bologna, Italy
    Ann Oncol 21:860-3. 2010
    ..Gemcitabine should be considered a suitable option. We report the long-term update of 39 pretreated T-cell lymphoma patients treated with gemcitabine...
  11. ncbi request reprint Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Lymphoma Myeloma Leuk 10:258-61. 2010
    ..Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database...
  12. ncbi request reprint High-dose therapy and stem cell transplantation
    Pier Luigi Zinzani
    University of Bologna, Bologna, Italy
    Semin Hematol 47:S15-7. 2010
    ..However, it is unclear whether there is a role for allogeneic transplant as a frontline treatment option...
  13. doi request reprint Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 117:1010-8. 2011
    ....
  14. doi request reprint Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 116:5667-75. 2010
    ..This study investigated the role of immunohistochemical discrimination between GCB and ABC&NC-DLBCL subtypes in identifying those high-risk patients who may benefit from a more aggressive first-line therapeutic approach...
  15. doi request reprint Hairy cell leukemia: evaluation of the long-term outcome in 121 patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Cancer 116:4788-92. 2010
    ..Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients...
  16. ncbi request reprint Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Via Massarenti 9, Bologna, Italy
    Clin Cancer Res 16:3998-4004. 2010
    ....
  17. doi request reprint PET in T-Cell Lymphoma
    Pier Luigi Zinzani
    Istituto di Ematologia L e A Seràgnoli, Bologna, Italy
    Curr Hematol Malig Rep 6:241-4. 2011
    ..Conversely, only a few studies have investigated the role of FDG-PET in T/NK-cell lymphomas. This paper summarizes the current information regarding the potential use of PET/CT in patients with T-cell lymphoma...
  18. doi request reprint Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L e A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma Leuk 11:462-6. 2011
    ..Here we report the results from a phase 2, single-arm, single-center trial evaluating the safety and efficacy of lenalidomide plus rituximab in elderly patients with relapsed or refractory DLBCL...
  19. ncbi request reprint Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease
    P L Zinzani
    Institute of Hematology, L e A Seragnoli, University of Bologna, Italy
    Haematologica 79:508-12. 1994
    ..Ideally, the cytotoxic agents should lack complete cross resistance with those utilized up front...
  20. doi request reprint A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Ann Oncol 19:769-73. 2008
    ....
  21. ncbi request reprint MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
    E Derenzini
    Department of Haematology and Medical Oncology, University of Bologna, Bologna, Italy
    Ann Oncol 21:1173-8. 2010
    ..Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care but prospective randomized trials are lacking...
  22. ncbi request reprint The role of positron emission tomography (PET) in the management of lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Ann Oncol 10:1181-4. 1999
    ..We investigated the ability of fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to differentiate between residual active tumor tissue and fibrosis...
  23. ncbi request reprint CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease
    P L Zinzani
    Institute of Hematology, L e A Seragnoli, University of Bologna, Italy
    Tumori 80:438-42. 1994
    ..Although initial treatment of Hodgkin's disease induces a complete remission in most patients, approximately 50% of patients with advanced disease will not achieve a complete remission or will relapse following the first complete remission...
  24. ncbi request reprint MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 42:989-95. 2001
    ..MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients...
  25. ncbi request reprint Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:926-9. 2000
    ..To assess the efficacy and the toxic profile of gemcitabine, a novel pyrimidine antimetabolite active against several solid tumors, we carried out a study in heavily pretreated Hodgkin's disease (HD) patients...
  26. ncbi request reprint Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Ann Oncol 11:363-5. 2000
    ..The aim of this study was to define the therapeutic efficacy and toxicity of a combination of FLU and mitoxantrone (FN regimen) in untreated LG-NHL...
  27. ncbi request reprint Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma
    Enrico Derenzini
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Cancer 113:2496-503. 2008
    ....
  28. ncbi request reprint Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
    P L Zinzani
    Institute of Hematology and Medical Oncology and University of Bologna, Bologna, Italy
    J Clin Oncol 18:773-9. 2000
    ..A first comparative trial of fludarabine (FLU) alone versus FLU plus idarubicin (FLU-ID) for indolent or mantle-cell lymphomas...
  29. ncbi request reprint Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:922-5. 2000
    ..Thus, it is important to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL...
  30. ncbi request reprint Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40121 Bologna, Italy
    Haematologica 86:287-90. 2001
    ....
  31. ncbi request reprint Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients
    P L Zinzani
    Institute of Hematology Seragnoli, University of Bologna, Bologna
    Ann Oncol 13:1364-9. 2002
    ..Here we report a prospective, multicenter, randomized trial comparing the efficacy and toxicity of 8- and 12-week regimens of VNCOP-B plus G-CSF...
  32. pmc Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Br J Cancer 91:850-4. 2004
    ..PET negativity at restaging strongly suggests the absence of active disease; histopathological verification is important in patients who show PET positivity...
  33. ncbi request reprint Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, and Institute of Dermatology Immacolata, Rome, Italy
    J Clin Oncol 18:2603-6. 2000
    ..To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with a low-toxicity profile and activity in several solid tumors, in patients with relapsed or refractory cutaneous T-cell lymphomas...
  34. ncbi request reprint Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
    Enrico Derenzini
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 50:1824-9. 2009
    ..R-MACOP-B regimen followed by involved-field radiation on bulky presentation is safe and very effective in the treatment of young patients with low-risk DLBCL...
  35. ncbi request reprint CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report
    P L Zinzani
    Institute of Hematology L. e A. Sergnoli, University of Bologna, Italy
    Tumori 76:533-6. 1990
    ..Clinical and hematologic toxicities were irrelevant. This regimen was effective in inducing a good remission rate of low-grade NHL, but a longer follow-up for definitive conclusions is warranted...
  36. ncbi request reprint Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40121 Bologna, Italy
    Haematologica 85:1135-9. 2000
    ..A study update to assess long-term survival following fludarabine salvage treatment in previously treated patients with chronic lymphocytic lymphoma (CLL)...
  37. ncbi request reprint Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, and Nuclear Medicine, S Orsola Hospital, Italy
    Ann Oncol 17:1296-300. 2006
    ..It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients...
  38. ncbi request reprint Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
    Philip Went
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, Hematology and Hematopathology Units, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 24:2472-9. 2006
    ..We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD)...
  39. ncbi request reprint VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly
    Mariapaola Fina
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 48:2167-71. 2007
    ..Three CRs relapsed within 12 months from the completion of treatment. Clinical and hematological toxicity was moderate. This regimen was effective in inducing a good remission rate with moderate toxic effects in elderly DLBCL patients...
  40. ncbi request reprint Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 17:1254. 1999
    ..We report a retrospective analysis of 75 patients with nongastrointestinal low-grade MALT lymphoma, presenting their clinical, therapeutic, and follow-up data with respect to the initial location of the lymphoma...
  41. ncbi request reprint Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 43:1239-43. 2002
    ..PET restaging is very valuable for the identification of patients who would need appropriate second-line therapy because of the presence of residual active abdominal disease and should be made widely available in combination with CT...
  42. ncbi request reprint Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification
    S A Pileri
    Chair of Pathologic Anatomy and Lymphoma Unit, L and A Seràgnoli Institute of Haematology and Clinical Oncology, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Histopathology 41:482-509. 2002
    ..The more recent acquisitions on the pathobiology of DLBCLs are reviewed in the light of the authors' experience, aiming to contribute to the existing debate on the topic...
  43. ncbi request reprint Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway
    P P Piccaluga
    Hematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S Orsola Malpighi Hospital, Bologna University Medical School, Bologna, Italy
    Leukemia 28:1687-97. 2014
    ..Altogether, our data demonstrated that PDGFRA activity fosters PTCL/NOS proliferation via an autocrine loop. ..
  44. ncbi request reprint Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
    S A Pileri
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Leukemia 21:340-50. 2007
    ....
  45. ncbi request reprint Persistent agmination of lymphomatoid papulosis: an ongoing debate
    A Pileri
    Division of Dermatology, Department of Internal Medicine, Geriatrics and Nephrology, University of Bologna, Bologna, Italy
    Dermatology 225:131-4. 2012
    ..Persistent agmination of lymphomatoid papulosis (PALP) has been a matter of controversy in the literature, some authors suggesting that it represents composite lymphoma, others localized lymphomatoid papulosis (LyP)...
  46. pmc Myeloperoxidase expression by histiocytes in Kikuchi's and Kikuchi-like lymphadenopathy
    S A Pileri
    Pathology and Clinical Units, Institute of Hematology and Clinical Oncology L and A Seràgnoli, Bologna University, Bologna, Italy
    Am J Pathol 159:915-24. 2001
    ....
  47. pmc Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
    C Agostinelli
    Department of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University School of Medicine, Bologna, Italy
    J Clin Pathol 61:1160-7. 2008
    ....
  48. ncbi request reprint Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Ann Oncol 14:i43-5. 2003
  49. ncbi request reprint 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma
    Lapo Alinari
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 47:2096-101. 2006
    ..Sensitivity of 18F FDG-PET for extra-nodal MALT was 81%. The data show that 18FDG-PET is a useful diagnostic tool in order to stage, restage or monitor disease in patients with extra-nodal MALT lymphoma...
  50. ncbi request reprint Difficult diagnostic and therapeutic cases: CASE 1. true thymic hyperplasia in a patient treated for T-cell lymphoma
    Stefano Ascani
    Unit of Hematopathology, Institute of Hematology and Clinical Oncology L and A Seràgnoli, Bologna University, Bologna, Italy
    J Clin Oncol 22:953-4. 2004
  51. pmc Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
    P L Zinzani
    Institute of Hematology Seragnoli, University of Bologna, Bologna, Italy
    Ann Oncol 24:2892-7. 2013
    ..We report results from a long-term subset analysis of 57 patients with relapsed/refractory MCL from the NHL-003 phase II multicenter study of single-agent lenalidomide in patients with aggressive lymphoma..
  52. ncbi request reprint Indolent lymphoma: the pathologist's viewpoint
    S A Pileri
    Pathologic Anatomy and Unit of Haematopathology, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Bologna, Italy
    Ann Oncol 15:12-8. 2004
    ..The recent identification of the IRTA gene family corresponding to IG-like receptors differentially expressed in B-cells might contribute to their better understanding...
  53. ncbi request reprint 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models
    V Ambrosini
    Department of Nuclear Medicine, Policlinico S Orsola Malpighi, Bologna University Hospital, Bologna, Italy
    Q J Nucl Med Mol Imaging 54:689-97. 2010
    ..To our knowledge, Sorafenib has never been employed in human lymphoma. The aim of the present study was to assess the efficacy of Sorafenib in murine models of human anaplastic large cells lymphoma (ALCL) and Hodgkin lymphoma (HD)...
  54. ncbi request reprint The pathologist's view point. Part I--indolent lymphomas
    S A Pileri
    Service of Pathologic Anatomy and Haematopathology, Institute Hematology and Oncology L and A Seràgnoli, Bologna University, Policlinico S Orsola, Italy
    Haematologica 85:1291-307. 2000
    ..The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians...
  55. ncbi request reprint Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna Italy
    Haematologica 86:187-91. 2001
    ..Primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis has recently been recognized as a specific clinical and pathologic entity for which the best therapeutic approach seems to be a combination of chemotherapy and radiotherapy...
  56. ncbi request reprint Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients
    P L Zinzani
    Institute of Hematology and Oncology Seragnoli, Roma, Italy
    J Clin Oncol 16:1532-7. 1998
    ..In particular, soluble CD30 (sCD30) levels were elevated in most patients with Hodgkin's disease (HD) and anaplastic large-cell lymphoma (ALCL)...
  57. ncbi request reprint In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells
    P Tosi
    Istituto di Ematologia ed Oncologia Medica L e A Seràgnoli, Policlinico S Orsola, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 84:794-8. 1999
    ..In this study we evaluated the effects of the combination of fludarabine and gemcitabine, a deoxycytidine analog that has shown both in vitro and in vivo activity against a variety of solid tumors...
  58. ncbi request reprint Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna Italy
    Haematologica 85:729-32. 2000
    ..We investigated the therapeutic efficacy and toxicity of the three-drug-combination VBM (vinblastine, bleomycin, and methotrexate) regimen in a group of 19 elderly HD patients...
  59. ncbi request reprint The pathologist's view point. Part II --aggressive lymphomas
    S A Pileri
    Service of Pathologic Anatomy and Hematopathology, Institute of Hematology and Oncology L and A Seragnoli, Bologna University, Policlinico S Orsola, Italy
    Haematologica 85:1308-21. 2000
    ..The authors focus on the key features of aggressive B- and T-cell lymphomas, aiming to contribute to the cross-talk between pathologists and clinicians...
  60. pmc Hodgkin's lymphoma: the pathologist's viewpoint
    S A Pileri
    Pathologic Anatomy and Haematopathology, Bologna University, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    J Clin Pathol 55:162-76. 2002
    ..Treatments adjusted to the pathobiological characteristics of the tumour in at risk patients have been proposed and are on the way to being applied...
  61. ncbi request reprint Traditional treatment approaches in B-cell non-Hodgkin's lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 44:S6-14. 2003
    ..At present, for patients with untreated disseminated disease; recurrent disease; or high-grade disease in the presence of poor risk factors; alternative treatment strategies are needed...
  62. ncbi request reprint Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma
    Pier Luigi Zinzani
    Seràgnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy
    Cancer 100:2190-4. 2004
    ....
  63. ncbi request reprint High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Leuk Lymphoma 45:321-6. 2004
    ..Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further...
  64. doi request reprint Biology and treatment of follicular lymphoma
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Unit, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Expert Rev Hematol 2:533-47. 2009
    ..Novel approaches, including stem cell transplantation, monoclonal antibodies and innovative agents, should be then considered for improving long-term results...
  65. doi request reprint Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 27:1781-7. 2009
    ..However, there are no prospective studies investigating the value of serial FDG-PET over time in patients in complete remission...
  66. ncbi request reprint Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    J Clin Oncol 22:2654-61. 2004
    ..We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab...
  67. ncbi request reprint Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 45:1815-9. 2004
    ..These preliminary data suggest that FLUIC is a very active, well-tolerated regimen for young, untreated patients with advanced non-follicular LG-NHL...
  68. ncbi request reprint Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET
    Charoula S Tsamita
    Department of Nuclear Medicine, Institute of Emathology, Policlinico S Orsola Malpighi, Bologna, Italy
    Nucl Med Commun 29:705-10. 2008
    ..The aim of this study was to evaluate the clinical significance of positive axillary findings in patients with Hodgkin's disease and non-Hodgkin's lymphoma during follow-up with 18F-fluorodeoxyglucose-PET...
  69. doi request reprint Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET
    Stefano Fanti
    Unità Operativa di Medicina Nucleare, Padiglione 30, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Via Massarenti 9, 40138 Bologna, Italy
    Ann Nucl Med 22:429-32. 2008
    ..This case testifies the possibility of early relapse of lymphoma even in the case of negative interim PET; it also supports the usefulness of end-treatment PET scan in lymphoma patients...
  70. ncbi request reprint Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Universita di Bologna, Bologna, Italy
    Hematol J 5:S38-49. 2004
    ..Available clinical data therefore indicate that fludarabine has an important role to play in the treatment of patients with indolent NHL. Further, studies are warranted to identify the optimal fludarabine regimen for this patient group...
  71. ncbi request reprint Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Haematologica 89:309-13. 2004
    ..Although remission of hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) appears to be long lasting, few reports currently provide results from follow-up exceeding 5 years...
  72. ncbi request reprint Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica L e A Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:816-21. 2002
    ..We adopted the strategy of using salvage chemotherapy to debulk disease and simultaneously mobilize stem cells, using a regimen based on ifosfamide and etoposide, (drugs not usually used for front-line treatment)...
  73. ncbi request reprint Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Haematologica 87:1258-64. 2002
    ....
  74. ncbi request reprint Diffuse large B-cell lymphoma (DLBCL), anaplastic variant. report on a problematic case primarily arising in the stomach
    Stefano Aldo Pileri
    Pathologic Anatomy, Clinical and Pathology Lymphoma Units, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Italy
    Haematologica 87:ECR40. 2002
  75. pmc Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins
    Stefano A Pileri
    Istituto di Ematologia e Oncologia Medica, L e A Seràgnoli Unità Cliniche e di Anatomia Patologica, Universita di Bologna, Bologna, Italy
    Am J Pathol 162:243-53. 2003
    ..However, it differs from other aggressive B-cell lymphomas in that it shows defective immunoglobulin production despite the expression of OCT-2, BOB.1, and PU.1 transcription factors and the lack of IgV(H) gene crippling mutations...
  76. ncbi request reprint Primary bone lymphoma: experience with 52 patients
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica L and A Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 88:280-5. 2003
    ..A retrospective analysis was performed to assess the efficacy of various treatments of non-Hodgkin's primary bone lymphomas (PBL)...
  77. ncbi request reprint High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Italy
    Haematologica 88:522-8. 2003
    ..In this work we examine the characteristics and outcome of patients with Hodgkin's disease (HD) treated with high-dose therapy (HDT) and autologous transplantation at our Institute between 1982 to 2000...
  78. ncbi request reprint Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 44:821-4. 2003
    ..In conclusion, these data underline the diagnostic utility of BAL and the therapeutic efficacy of a chemotherapeutic strategy based on regimens such as N-CVP in the context of localized MALT lymphoma of the lung...
  79. ncbi request reprint Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L eA Seràgnoli, University of Bologna, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Crit Rev Oncol Hematol 48:S27-31. 2003
    ..The research of specific therapeutic protocols is needed to cure the elderly lymphoma patients reducing the risk of important toxic effects...
  80. doi request reprint Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 93:1033-8. 2008
    ..Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned...
  81. ncbi request reprint Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Lancet Oncol 9:352-8. 2008
    ....
  82. ncbi request reprint The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis
    Stefano A Pileri
    Lymphoma Study Group, Institute of Haematology and Clinical Oncology, Bologna University, Italy
    Haematologica 90:293. 2005
  83. ncbi request reprint Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays
    Pier Luigi Zinzani
    Pathologic Anatomy and Lymphoma Unit, Institute of Haematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Haematologica 90:341-7. 2005
    ..Patients with diffuse large B-cell lymphoma (DLBCL) could benefit from integration of well-established bioclinical prognostic factors with new tools - such as micro-arrays - exploring aberrant gene and/or protein expression...
  84. ncbi request reprint Thoughts on the eradication of Helicobacter pylori infection in localized gastric mucosa-associated lymphoid tissue lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 47:2013-4. 2006
  85. ncbi request reprint Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:115-24. 2006
    ..These could include the use of more efficient preparative and purging approaches in the transplantation setting or the administration of rituximab maintenance therapy after (immuno) chemotherapy induction or transplantation...
  86. ncbi request reprint Primary gastric diffuse large-cell lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:1201-2. 2006
  87. ncbi request reprint Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 24:1376-82. 2006
    ..Primary cutaneous B-cell lymphomas (PCBCLs) are a distinct group of primary cutaneous lymphomas with few and conflicting data on their prognostic factors...
  88. ncbi request reprint Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  89. ncbi request reprint Lymphoma: diagnosis, staging, natural history, and treatment strategies
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Italy
    Semin Oncol 32:S4-10. 2005
    ..Strategies using various chemotherapy combinations, including innovative agents such as 90 Y-ibritumomab tiuxetan, show promise in the treatment of NHL, particularly indolent NHL, and hopefully will lead to an improvement in prognosis...
  90. ncbi request reprint Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified
    Pier Paolo Piccaluga
    Institute for Cancer Genetics, Columbia University, New York, NY, USA
    Lancet Oncol 6:440. 2005
  91. ncbi request reprint Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna
    Leuk Lymphoma 46:1449-54. 2005
    ..985; p = 0.049). Post-treatment hemoglobin values appear to provide a strong independent predictor of 5-year survival in elderly aggressive NHL, supporting the potential role of anemia correction in this group of patients...
  92. ncbi request reprint Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas
    Pier Luigi Zinzani
    L and A Seragnoli Institute of Hematology and Oncology, University of Bologna, Bologna, Italy
    Acta Haematol 114:255-9. 2005
    ..In the last decade, autologous hematopoietic stem cell transplantation has played an important role in front-line and salvage treatments of indolent and aggressive NHL...
  93. pmc Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 117:823-34. 2007
    ..These results, which might be extended to other more rare PTCL categories, provide insight into tumor pathogenesis and clinical management of PTCL/U...
  94. ncbi request reprint Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:291-5. 2007
    ..The purpose of this study was to evaluate the reliability of positron emission tomography (PET) in patients with follicular lymphoma (FL) after induction treatment...
  95. doi request reprint A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Cancer 112:856-62. 2008
    ....
  96. doi request reprint Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
    Eur J Cancer 44:366-73. 2008
    ..This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas...
  97. ncbi request reprint Histopathology of B-cell chronic lymphocytic leukemia
    Stefano A Pileri
    Unit of Haematopathology, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Hematol Oncol Clin North Am 18:807-26, viii. 2004
    ..The relevance of the examination of trephines and surgical specimens is outlined with special reference to the identification of risk factors in individual patients...
  98. ncbi request reprint Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:566-72. 2007
    ..The purpose of this review is to point out the state of the art regarding bronchus-associated lymphoid tissues lymphomas in terms of etiology, pathogenesis, clinics, and therapeutics, including our single-center experience of 23 cases...
  99. ncbi request reprint Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Res 67:10703-10. 2007
    ..Our study provides new relevant information on AILT biology and new candidates for possible therapeutic targets such as PDGFRA (platelet-derived growth factor alpha) and VEGF...
  100. ncbi request reprint Rituximab in primary conjunctiva lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Leuk Res 29:107-8. 2005
    ..Our experience with a patient with a primary conjunctiva lymphoma who was treated with conventional dose of rituximab obtaining a complete response without acute and late local toxicity for the eye...
  101. ncbi request reprint Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma
    Gianluca Brusa
    Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, Università di Bologna Medical School, 40138 Bologna, Italy
    Oncol Rep 18:1427-34. 2007
    ..Immunohistochemistry confirmed aCGH results and distinguished the distribution of either amplified or deleted gene products in neoplastic Reed Sternberg (RS) cells and non-neoplastic lymph node components...